For help on how to get the results you want, see our search tips.
1060 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Opinions on medicines for use outside EU Remove Opinions on medicines for use outside EU filter
Categories
Human Remove Human filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Momelotinib (updated)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-001656-PIP02-19, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 17/06/2019, Last updated: 28/09/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Sotrastaurin acetate (updated)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-000093-PIP02-10, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate dosage form, other
Decision date: 26/01/2011, Last updated: 15/09/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Rimegepant
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Neurology
PIP number: EMEA-002812-PIP01-20, Route(s) of administration: Oral use, Pharmaceutical form(s): Orodispersable Tablets
Decision date: 12/08/2020, Last updated: 01/08/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): IMG-2789
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-002752-PIP01-19, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 16/06/2020, Last updated: 14/06/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oto-rhino-laryngology
PIP number: EMEA-001501-PIP08-20, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 17/03/2021, Last updated: 28/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Recombinant porcine factor VIII, B-domain deleted
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-000753-PIP01-11, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for solution for injection, Powder and solvent for solution for injection
Decision date: 24/02/2012, Last updated: 10/10/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): In vitro expanded autologous human articular chondrocytes
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Other
PIP number: EMEA-002217-PIP01-17-M02, Route(s) of administration: Intraarticular use, Pharmaceutical form(s): Implant
Decision date: 12/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Elafibranor
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001857-PIP02-20, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 12/08/2020, Last updated: 10/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tislelizumab
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002480-PIP01-18, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 17/04/2019, Last updated: 27/06/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): octenidine dihydrochloride
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Neonatology-Paediatric Intensive Care
PIP number: EMEA-001384-PIP01-12, Route(s) of administration: Cutaneous use, Pharmaceutical form(s): Cutaneous solution
Decision date: 21/12/2016, Last updated: 29/11/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): idecabtagene vicleucel
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002369-PIP01-18-M02, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Dispersion for injection
Decision date: 19/02/2021, Last updated: 08/10/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Lartruvo, Olaratumab
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-001760-PIP01-15-M03, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 22/03/2019, Last updated: 08/10/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): (1R,2R,3S,4S,5R,6S)-cyclohexane-1,2,3,4,5,6-hexayl-hexakis (dihydrogen phosphate)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Other
PIP number: EMEA-002854-PIP01-20, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for infusion
Decision date: 01/12/2020, Last updated: 22/09/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Linerixibat
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-002800-PIP01-20, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet
Decision date: 09/09/2020, Last updated: 01/07/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Anti-neonatal Fc receptor human monoclonal antibody
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Other
PIP number: EMEA-002559-PIP01-19, Route(s) of administration: Intravenous use, Subcutaneous use, Pharmaceutical form(s): Concentrate for solution for infusion, Solution for injection
Decision date: 16/08/2019, Last updated: 01/07/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Viekirax, Ombitasvir, paritaprevir, ritonavir
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-001440-PIP01-13-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet, Age-appropriate oral solid dosage form
Decision date: 12/08/2020, Last updated: 30/06/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ariclaim, duloxetine hydrochloride
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Uro-nephrology
PIP number: EMEA-000420-PIP01-10, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard, Gastro-resistant capsule
Decision date: 17/11/2010, Last updated: 22/06/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Victrelis, Boceprevir
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-000583-PIP01-09-M08, Route(s) of administration: Oral use, Pharmaceutical form(s): Granules, Capsule, hard
Decision date: 17/04/2020, Last updated: 05/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Varuby, rolapitant
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001768-PIP02-15-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral dosage form
Decision date: 15/05/2020, Last updated: 04/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): belantamab mafodotin
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002468-PIP04-18, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for concentrate for solution for infusion
Decision date: 11/09/2020, Last updated: 19/02/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): ambrisentan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-002030-PIP01-16, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 30/01/2017, Last updated: 19/02/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Levothyroxine (sodium)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism
PIP number: EMEA-002259-PIP01-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral solution
Decision date: 16/03/2018, Last updated: 29/07/2020, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Aciclovir
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-001066-PIP02-11-M03, Route(s) of administration: Gingival use, Pharmaceutical form(s): Muco-adhesive buccal tablet
Decision date: 04/12/2019, Last updated: 01/04/2020, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Daklinza, Daclatasvir
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-001191-PIP01-11-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Chewable tablet, Film-coated tablet
Decision date: 08/11/2019, Last updated: 30/03/2020, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Influenza virus surface antigens (haemagglutinin) of strain A (H1N1), influenza virus surface antigens (haemagglutinin) of strain A (H3N2), influenza virus surface antigens (haemagglutinin) of strain B (Victoria lineage), influenza virus surface antigens (haemagglutinin) of strain B (Yamagata lineage)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-002027-PIP02-17-M01, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Suspension for injection
Decision date: 10/09/2019, Last updated: 26/03/2020, Compliance check: X